Boulder Diagnostics, RUNMC enter agreement to market Lyme disease diagnostic test

NewsGuard 100/100 Score

Boulder Diagnostics Inc. and the Department of Internal Medicine, Radboud University Nijmegen Medical Centre (RUNMC) announced today the entry into a license and collaboration agreement to market the innovative Lyme disease diagnostic test developed at RUNMC. Under the agreement Boulder will finance further research at the Department of Internal Medicine, and RUNMC will be entitled to royalties on future sales of the licensed technology. Further details were not disclosed.

“The collaboration with Boulder Diagnostics allows us to extend the benefit of our innovative diagnostic technology beyond our institution”

The new powerful Lyme disease diagnostic test is particularly suited to detect a chronic Lyme infection from a patient blood sample. By reading out unique biological responses the new test can achieve unprecedented specificity without requiring invasive biopsy procedures. It avoids the notoriously low accuracy of typical serology based tests.

"We are excited to work with the Internal Medicine Department of Radboud University Nijmegen Medical Centre to bring this transformative and reliable Lyme disease test to the market in the near future", says Wolfgang Pieken, CEO of Boulder Diagnostics Inc.

"The collaboration with Boulder Diagnostics allows us to extend the benefit of our innovative diagnostic technology beyond our institution", comments Leo Joosten, Associate Professor of Experimental Medicine at Radboud University Nijmegen Medical Centre. "This assay holds the potential to significantly reduce the frequent misdiagnosis of chronic borrelia infection", adds Mihai Netea, Professor of Experimental Medicine.

Source:

 Boulder Diagnostics and Radboud University Nijmegen Medical Center

Comments

  1. Walter Selens Walter Selens United States says:

    This article was much too brief to cover the enormous amount of questions that came to mind, strictly from the statement of "New Lyme Test". They do state that the test is a simple blood sample, but it doesn't state: 1) what markers are they looking for, 2) what are the parameters of those markers 3) at what point do they consider someone "chronic" versus "acute", 4) Do acute patients show positive with this test? Also, more importantly, I would like to know what the political stance of this company is, to see how they are involved with the CDC, ILSAD, and their views on the existance of Chronic Lyme altogether.  They did state that this disease is often mis/under diagnosed, but I would like to see more evidence that they are there for the patient, not the doctors that say this disease doesn't exist.

  2. natasja natasja Ireland says:

    One thing I know for sure in Holland I did not have that much trouble to be reconize that I have lyme disease as it is a big problem and they know that we have a lot of trouble with the ticks over there even the media and tv worn every time about it as even most all most every GP in holland will confirm that

    I realy was better of there with lyme disease and funny part is I even got it over there on my holiday

    and that medical centre i know very well and what that hospital in nijmegen Radboud does and must say they are very high standerd and very good also be postitive that centre does not do any thing in first way for the politic but for the human and people paitients.

    i know because it is my home town

    i only hope that they here will learn somthing from it  

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Genetic link between PTSD and Alzheimer's debunked in veterans study